Women’s health encompasses all different areas of medicine and it would be a monumental task to address all of the areas that affect women. This report will concentrate on disorders that affect the female reproductive system and other disorders where there is at least a 70% preponderance of women affected by the disorder. The worldwide prescription drug market for women’s health consists of total manufacturers’ revenues from the following product categories:

• Autoimmune diseases
• Cancer
• Gynecological and Sexually Transmitted Diseases
• Hormones
• Osteoporosis
• Urinary Disorders

Women's Health: Worldwide Prescription Drug Markets, represents the fourth time that Kalorama Information has tackled the women's health pharmaceutical market. Revenues from these segments are not reported in total, as certain segments affect both men and women. The analysis and market data in this report estimate revenues associated with therapeutics for women only. Segmentation within each category is by major drug type and by geographic region (U.S., Europe, Japan, ROW). All market data pertain to the U.S. market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2007. forecast data are provided for each of the years 2009 through 2013. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2007 base year.

In addition to market data, the report contains extensive product pipeline information, competitor profiles, and discussions of the major industry issues and trends shaping the market.

The information and analysis presented in this report are based on an extensive survey of senior management in the prescription women’s health drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 40 industry executives and product managers to validate and obtain expert opinion on current and future trends in the women’s health industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.

Related Reports:

Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads
Nov 1, 2009 - KLI2403357 - $3,995.00

The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
Oct 1, 2009 - KLI2435380 - $3,500.00

The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets
Oct 1, 2009 - KLI2384194 - $3,995.00

The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition
May 1, 2009 - KLI2218043 - $3,995.00

Rx to OTC Switches 2009
May 1, 2009 - KLI2196300 - $3,500.00

Pharmaceutical Outsourcing Post-Launch : Contract Manufacturing, Biomanufacturing and Sales, 3rd Edition
Jan 1, 2009 - KLI1646605 - $3,500.00

Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition
Nov 1, 2008 - KLI1646591 - $3,995.00

Pharmaceutical Markets in Brazil, Russia, India and China ( BRIC nations )
Jul 1, 2008 - KLI1614109 - $2,500.00

The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies
Apr 1, 2008 - KLI1692599 - $1,995.00

World Market for Prescription Generic Drugs, 6th Edition
Apr 1, 2008 - KLI1614095 - $3,995.00